GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Therma Bright Inc (TSXV:THRM) » Definitions » Sloan Ratio %

Therma Bright (TSXV:THRM) Sloan Ratio % : 0.00% (As of Jul. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Therma Bright Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Therma Bright's Sloan Ratio for the quarter that ended in Jul. 2024 was 0.00%.

Warning Sign:

When sloan ratio (-40.88)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Jul. 2024, Therma Bright has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Therma Bright Sloan Ratio % Historical Data

The historical data trend for Therma Bright's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therma Bright Sloan Ratio % Chart

Therma Bright Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -243.26 -46.89 -40.81 -40.88

Therma Bright Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Therma Bright's Sloan Ratio %

For the Medical Devices subindustry, Therma Bright's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therma Bright's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Therma Bright's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Therma Bright's Sloan Ratio % falls into.



Therma Bright Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Therma Bright's Sloan Ratio for the fiscal year that ended in Jul. 2024 is calculated as

Sloan Ratio=(Net Income (A: Jul. 2024 )-Cash Flow from Operations (A: Jul. 2024 )
-Cash Flow from Investing (A: Jul. 2024 ))/Total Assets (A: Jul. 2024 )
=(-2.451--1.009
--0.138)/3.19
=-40.88%

Therma Bright's Sloan Ratio for the quarter that ended in Jul. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jul. 2024 )
=(-2.451--1.009
-0)/3.19
=-45.20%

Therma Bright's Net Income for the trailing twelve months (TTM) ended in Jul. 2024 was -0.144 (Oct. 2023 ) + -0.113 (Jan. 2024 ) + -0.322 (Apr. 2024 ) + -1.872 (Jul. 2024 ) = C$-2.45 Mil.
Therma Bright's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jul. 2024 was -0.172 (Oct. 2023 ) + 0.008 (Jan. 2024 ) + 0.107 (Apr. 2024 ) + -0.952 (Jul. 2024 ) = C$-1.01 Mil.
Therma Bright's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jul. 2024 was 0 (Oct. 2023 ) + 0 (Jan. 2024 ) + 0 (Apr. 2024 ) + 0 (Jul. 2024 ) = C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therma Bright  (TSXV:THRM) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jul. 2024, Therma Bright has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Therma Bright Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Therma Bright's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Therma Bright Business Description

Traded in Other Exchanges
Address
345 Danforth Avenue, Toronto, ON, CAN, M4K 1N7
Therma Bright Inc is a developer and partner in a range of proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with solutions to address important medical and healthcare challenges. The Company is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on 3 key strategic areas: respiratory disease, vascular health, and consumer medical devices.
Executives
Joseph Ching-hiang Heng Director
Roberto Fia Director, Senior Officer
David J. Woods 10% Security Holder